Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Rejects Advice To Delay Second Dose Of Pfizer Vaccine

Health Minister Says Move Not Justified By The Evidence

Executive Summary

The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine. 

You may also be interested in...



Coronavirus Notebook: EFPIA Attacks EU’s Vaccine Export Authorization Scheme, EMA Starts Rolling Review Of REGN-COV2 Antibody Combo

Médecins Sans Frontières has urged Johnson & Johnson to prioritize vaccine supplies to COVAX, the EMA has clarified the dosing interval for Pfizer/BioNTech’s Comirnaty, and the UK has ordered more vaccine from Valneva.

French HTA Body Backs Routine Six-Week Interval In COVID-19 Vaccine Dosing

France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.

EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods

Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel